Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
1. A method for treating a cancer comprising administering to a subject having the cancer one or more immune checkpoint inhibitors, and administering to the subject hematopoietic stem cells, in amounts effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and/or V-domain Ig suppressor of T cell activation (VISTA), and wherein the source of hematopoietic stem cells is autologous or wherein the source of hematopoietic stem cells is allogenic and the donor cells are HLA-matched to the recipient.
2. The method of claim 1 , wherein the cancer is resistant to monotherapy treatment with the one or more immune checkpoint inhibitors.
3. The method of claim 1 , wherein the PD-1 antagonist is an agent that binds to and antagonizes PD-1.
4. The method of claim 3 , wherein the agent that binds to and antagonizes PD-1 is a peptide that binds PD-1 or a humanized antibody that selectively binds PD-1.
5. The method of claim 1 , wherein the PD-L1 antagonist is an agent that binds to and antagonizes PD-L1.
6. The method of claim 5 , wherein the agent that binds to and antagonizes PD-L1 is a peptide that binds PD-L1 or a humanized antibody that selectively binds PD-L1.
7. The method of claim 1 , wherein the VISTA antagonist is an agent that binds to and antagonizes VISTA.
8. The method of claim 7 , wherein the agent that binds to and antagonizes VISTA is:
(i) a peptide,
(ii) an inhibitory antibody directed to VISTA,
(iii) an antisense molecule directed against VISTA,
(iv) an adnectin directed against VISTA,
(v) a single stranded or double stranded RNAi inhibitor of VISTA, or
(vi) a small molecule inhibitor of VISTA.
9. The method of claim 1 , wherein the immune checkpoint inhibitor is administered on the same day or on different day than the hematopoietic stem cell transplantation.
10. The method of claim 1 , further comprising administering to the subject a hematopoietic stem cell mobilizing agent.
11. The method of claim 1 , wherein the cancer is melanoma, squamous cell carcinoma, basal cell carcinoma, breast cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, bone sarcoma, testicular cancer, prostatic cancer, ovarian cancer, bladder cancer, skin cancer, brain cancer, glioblastoma, medulloblastoma, ependymoma, angiosarcoma, hemangiosarcoma, mast cell tumor, primary hepatic cancer, small cell lung cancer, non-small-cell lung cancer, pancreatic cancer, gastrointestinal cancer, renal cell carcinoma, hematopoietic neoplasia, lymphoma, mesothelioma, glioblastoma, low-grade glioma, high-grade glioma, pediatric brain cancer, medulloblastoma, or a metastatic cancer thereof.
12. The method of claim 1 , wherein the source of hematopoietic stem cells is bone marrow, bone marrow lineage depleted cells (lin−), cKit+purified lineage negative bone marrow derived cells, Sca+purified lineage negative bone marrow derived cells, cKit+Sca+purified bone marrow derived cells, mobilized from host bone marrow using GM-CSF, G-CSF, mobilized from host bone marrow using AMD3100, Plerixafor, or the molecule 1,1′-[1,4-phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane], umbilical cord blood or cord-blood derived stem cells, human leukocyte antigen (HLA)-matched blood, mesenchymal stem cells derived from blood or marrow, hematopoietic stem cells differentiated from induced pluripotent stem cells, mobilized peripheral blood, peripheral blood, hematopoietic stem cell subsets including lin− cells purified with CCR2+ marker, lineage negative purified peripheral blood, or CD34+ enriched peripheral blood.
13. The method of claim 1 , wherein an effect of the treatment on the cancer is assessed by measuring interferon gamma (IFNγ) secretion by T cells obtained from within a tumor microenvironment or tumor draining lymph nodes of the subject, wherein a synergistic effect is noted if the presence of IFNγ is increased with combination therapy.
14. The method of claim 1 , wherein at least 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 percent of the hematopoietic stem cells are CCR2 positive (CCR2+), CD34 positive (CD34+), and/or lineage negative (lin−) cells.
15. The method of claim 1 , wherein the hematopoietic stem cells for administration to the subject are enriched ex-vivo for CCR2 positive (CCR2+) cells, for CD34 positive (CD34+) cells and/or for lineage negative (lin−) cells prior to administration to the subject.
16. The method of claim 1 , wherein the hematopoietic stem cells are processed ex-vivo to deplete CCR2 negative (CCR2−) cells before administration to the subject.
17. The method of claim 1 , wherein the PD-L2 antagonist is an agent that binds to and antagonizes PD-L2.
18. The method of claim 17 , wherein the agent that binds to and antagonizes PD-L2 is a peptide that binds PD-L2 or a humanized antibody that selectively binds PD-L2.
19. The method of claim 1 , wherein the immune checkpoint inhibitor is administered within 3 months of the hematopoietic stem cells.
20. The method of claim 1 , wherein the immune checkpoint inhibitor is administered within 1 month of the hematopoietic stem cells.
21. The method of claim 1 , wherein the immune checkpoint inhibitor is administered within 1 week of the hematopoietic stem cells.
22. The method of claim 1 , wherein the immune checkpoint inhibitor is administered within 1 day of the hematopoietic stem cells.
23. A method for treating a cancer comprising administering to a subject having the cancer one or more immune checkpoint inhibitors, and administering a hematopoietic stem cell mobilizing agent, in amounts effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and/or V-domain Ig suppressor of T cell activation (VISTA).
24. A method for treating a cancer in a subject receiving immune checkpoint inhibitor therapy for the cancer, comprising administering to the subject hematopoietic stem cells in an amount which, in combination with the immune checkpoint inhibitor therapy, is effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and/or V-domain Ig suppressor of T cell activation (VISTA).
25. A method for treating a cancer in a subject receiving hematopoietic stem cell transplantation therapy for the cancer, comprising administering to the subject one or more immune checkpoint inhibitors in an amount which, in combination with the hematopoietic stem cell transplantation therapy, is effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and/or V-domain Ig suppressor of T cell activation (VISTA).
26. A method of treating a subject comprising, administering a stem cell mobilizing agent to the subject, harvesting hematopoietic stem cells from the subject, enriching the harvested stem cells for CCR2 positive (CCR2+), CD34 positive (CD34+), or lineage negative (lin−) cells, administering to the subject the enriched harvested stem cells, and administering to the subject an immune checkpoint inhibitor, wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and/or V-domain Ig suppressor of T cell activation (VISTA).